Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

NCT00448383 ·Status: COMPLETED ·Phase: PHASE3

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan

NCT02616380 ·Status: COMPLETED

A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis

NCT00443651 ·Status: COMPLETED ·Phase: PHASE3

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

NCT01712178 ·Status: COMPLETED ·Phase: PHASE2

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

NCT00049751 ·Status: COMPLETED ·Phase: PHASE3

Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

NCT01078090 ·Status: COMPLETED

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

NCT01893996 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

NCT01077258 ·Status: COMPLETED

Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy

NCT01021735 ·Status: COMPLETED ·Phase: PHASE4

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

NCT01752855 ·Status: COMPLETED ·Phase: PHASE2

Quality of Life Study With Adalimumab in Rheumatoid Arthritis

NCT00234936 ·Status: COMPLETED ·Phase: PHASE3

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

NCT06037811 ·Status: RECRUITING ·Phase: PHASE2

Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice

NCT01736189 ·Status: COMPLETED

Targeted Ultrasound in Rheumatoid Arthritis

NCT02056184 ·Status: COMPLETED ·Phase: PHASE4

Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis

NCT00234897 ·Status: COMPLETED ·Phase: PHASE4

Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents

NCT01783730 ·Status: COMPLETED

Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT00235859 ·Status: COMPLETED ·Phase: PHASE3

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

NCT06016517 ·Status: NOT_YET_RECRUITING

Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)

NCT00396812 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

NCT00124982 ·Status: COMPLETED ·Phase: PHASE3

Long Term Open Label Continuation Study

NCT00195650 ·Status: COMPLETED ·Phase: PHASE3

Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

NCT01561313 ·Status: COMPLETED ·Phase: PHASE2

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

NCT00235872 ·Status: COMPLETED ·Phase: PHASE3

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

NCT01502423 ·Status: COMPLETED ·Phase: PHASE2

A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate

NCT00266227 ·Status: COMPLETED ·Phase: PHASE3